Searchable abstracts of presentations at key conferences in endocrinology

ea0050p390 | Thyroid | SFEBES2017

Thyrotrophin receptor antibodies (TRAb) and other autoantibodies after treatment of Graves’ disease

Nalla Preethi , Young Stuart , Sanders Jane , Adlan Mohamed , Furmaniak Judwiga , Chen Shue , Rees Smith Bernard , Premawardhana Lakadasa

Introduction: Following treatment of Graves’ disease (GD), levels of thyrotropin receptor autoantibodies (TRAb) tend to decrease depending on treatment modality and length of follow up. We have assessed TRAb biological activity at follow up, years after GD treatment.Subjects and methods: TRAb concentration and biological activity were measured in 69 GD patients (59 females; 10 males; median age 59 years; TRAb positive at diagnosis), with follow up r...

ea0050p390 | Thyroid | SFEBES2017

Thyrotrophin receptor antibodies (TRAb) and other autoantibodies after treatment of Graves’ disease

Nalla Preethi , Young Stuart , Sanders Jane , Adlan Mohamed , Furmaniak Judwiga , Chen Shue , Rees Smith Bernard , Premawardhana Lakadasa

Introduction: Following treatment of Graves’ disease (GD), levels of thyrotropin receptor autoantibodies (TRAb) tend to decrease depending on treatment modality and length of follow up. We have assessed TRAb biological activity at follow up, years after GD treatment.Subjects and methods: TRAb concentration and biological activity were measured in 69 GD patients (59 females; 10 males; median age 59 years; TRAb positive at diagnosis), with follow up r...

ea0090p134 | Pituitary and Neuroendocrinology | ECE2023

Efficacy and Safety Analysis of Setmelanotide As a Novel Treatment for Hypothalamic Obesity

Roth Christian L. , Shoemaker Ashley H. , Gottschalk Michael , Miller Jennifer L. , Yuan Guojun , Chen Evan , Scimia Cecilia , Jennifer Abuzzahab M.

Background: Hypothalamic injury and impaired melanocortin-4 receptor (MC4R) pathway signaling, often a result of surgery or radiation for a benign tumor, may lead to hypothalamic obesity (HO). After injury, sudden weight gain and appetite changes unresponsive to existing therapies develop. Setmelanotide, an MC4R agonist, is approved for chronic weight management in patients with certain MC4R pathway–associated diseases. We report interim results of a Phase 2 study of setm...

ea0063oc1.4 | Calcium and Bone | ECE2019

Risk of sepsis, respiratory infections, and kidney or other genitourinary (GU) infections in patients with chronic hypoparathyroidism (HypoPT): a retrospective cohort study

Chen Kristina , Curhan Gary , Gosmanova Elvira , Mu Fan , Briggs Allison , Pajerowski William , Sherry Nicole , Ketteler Markus , Rejnmark Lars

Background: Prior small studies have suggested increased risk of infections in patients with hypoparathyroidism (HypoPT). This study using a large managed care cohort evaluated whether chronic HypoPT is associated with increased risk of sepsis, respiratory infections, and kidney or other genitourinary (GU) infections.Methods: A retrospective cohort study using a US commercial claims database (Q1 2007–Q2 2017) was conducted to examine the association...

ea0063gp147 | Interdisciplinary Endocrinology 1 | ECE2019

Risk of nephrolithiasis and nephrocalcinosis in patients with chronic hypoparathyroidism (HypoPT): a retrospective cohort study

Chen Kristina , Curhan Gary , Gosmanova Elvira O. , Rejnmark Lars , Swallow Elyse , Macheca Monica , Briggs Allison , Sherry Nicole , Ketteler Markus

Background: Little is known about the risk of developing nephrolithiasis and nephrocalcinosis in patients with chronic HypoPT treated with conventional therapy (ie, oral calcium and active vitamin D). This study evaluated whether HypoPT is associated with increased risk of these conditions.Methods: This retrospective cohort study, based on a large US commercial claims database (Q1 2007–Q2 2017), was conducted to compare the risk of nephrolithiasis a...

ea0063gp149 | Interdisciplinary Endocrinology 1 | ECE2019

Risk of chronic kidney disease (CKD) and CKD progression in patients with chronic hypoparathyroidism (HypoPT): a retrospective cohort study

Chen Kristina , Gosmanova Elvira O. , Curhan Gary , Rejnmark Lars , Mu Fan , Swallow Elyse , Sherry Nicole , Macheca Monica , Ketteler Markus

Background: Previous studies of smaller size signaled heightened risk of CKD in patients with chronic HypoPT treated with conventional therapy (ie, oral calcium and active vitamin D). However, little is known about CKD progression, including progression to end-stage kidney disease (ESKD), in HypoPT patients.Methods: A retrospective cohort study, using a large US commercial claims database (Q1 2007–Q2 2017), was conducted to compare the risk of CKD b...

ea0063p1038 | Interdisciplinary Endocrinology 2 | ECE2019

Risk of type 2 diabetes (T2D) in patients with chronic hypoparathyroidism (HypoPT): A retrospective cohort study

Chen Kristina , Gosmanova Elvira O , Curhan Gary , Mu Fan , Macheca Monica , Warchol Marie , Sherry Nicole , Ketteler Markus , Rejnmark Lars

Background: Among chronic hypoparathyroidism (HypoPT) patients, the baseline prevalence of type 2 diabetes (T2D) appeared to be higher than the general population in previous studies. Since little is known about the potential assocation between HypoPT and T2D, this study evaluated whether HypoPT is associated with increased risk of T2D.Methods: A retrospective cohort study, based on a US commercial claims database (Q1 2007 – Q2 2017), was conducted ...

ea0049oc14.2 | Thyroid Cancer | ECE2017

Suppression of heme oxygenase-1 inhibits growth and invasion of thyroid cancer

Cheng Shih-Ping , Lee Jie-Jen , Chen Ming-Jen , Liu Chien-Liang , Yang Po-Sheng , Hsu Yi-Chiung

Oxidative stress generated in the process of iodide metabolism and thyroid hormone synthesis may play a role in thyroid tumorigenesis and progression of thyroid cancer. The transcription factor Nrf2 is the most important regulator of antioxidant responses. It has been shown that Nrf2 expression is upregulated in papillary thyroid cancer. In response to oxidative stress, nuclear Nrf2 activates antioxidant-responsive elements and induces the expression of stress-responsive genes...

ea0041gp15 | Adrenal (1) | ECE2016

Reduced temperature and the chemical chaperone 4-phenylbutyrate enhance stability of CYP21A2 mutations

Chen Yiqing , Schaefer Kerstin , Gasteiger Maria , Taylor Angela , Arlt Wiebke , Krone Nils , Gersting Soeren W. , Reisch Nicole

Background: Mutations of 21-hydroxylase (CYP21A2) cause congenital adrenal hyperplasia. Its severe (classic) form constitutes a life-threatening disease. Patients suffer a significant disease burden due to co-morbidities that are often treatment-related. The current therapeutic situation is unsatisfying and demands novel treatment approaches. In silico modelling suggests protein misfolding and intracellular retention to play a significant role in the pathogenesis of C...

ea0038p320 | Pituitary | SFEBES2015

Neuronatin emerges in the rat pituitary stem/progenitor cells and terminates its role in the terminally differentiating cells

Kanno Naoko , Higuchi Masahi , Yoshida Saishu , Yako Hideji , Chen Mo , Ueharu Hiroki , Nishimura Naoto , Nishihara Hiroto , Kato Takako , Kato Yukio

The pituitary gland that synthesises and secretes pituitary hormones is an indispensable endocrine organ. Its development progresses by plural factors. Among them, neuronatin (NNAT), which was discovered in the neonatal mouse brain and is involved in neural development, was later revealed to be an abundantly expressing gene in the pituitary gland, but its role is yet elusive.We analysed the expression profile of Nnat and its localisation in the ...